

ASX Announcement

Medibio Limited – 1 September 2021



CEO/MD Remuneration Update and Company Secretary Resignation

Melbourne, Australia and Minneapolis, MN – 1 September 2021: Medibio Limited (Medibio or the Company) (ASX: MEB) (OTCPINK: MDBIF), wishes to advise changes to the remuneration terms of the Company's Chief Executive Officer ("CEO") and Managing Director ("MD"), Mr Claude Solitario.

Mr Solitario was appointed as the Company's CEO and MD in January 2020. As CEO and MD, Mr Solitario is focused on managing the regulated as well as non-regulated business units of the Company along with outlining and progressing on a strategic roadmap for Company's project portfolio in Australia and the US. Since his appointment, Mr Solitario has made a significant contribution to date and the Company looks forward to his continued leadership.

Mr Solitario's remuneration has been updated to bring his remuneration in line with market rates. In addition, Mr Solitario's new remuneration includes a number of financial and non-financial Key Performance Indicators ("KPIs") that better align his performance outcomes to the Company's business plan and objectives.

A summary of the revised remuneration terms for Mr Solitario, effective from the 1 July 2021, are set out below:

Total Fixed Remuneration (TFR):	\$200,000 per annum (inclusive of statutory superannuation)
Short Term Incentive (STI):	30% of TFR for FY22, payable in cash or securities based on achievement of certain KPIs and performance objectives as determined by the Board

All other terms of Mr Solitario's executive services agreement with the Company remain unchanged.

Resignation of Joint Company Secretary

The Company also wishes to advise that Ms Melanie Leydin has resigned from the position of Joint Company Secretary of the Company.

Ms Leydin will continue to support Medibio in her capacity as Non-executive Director. Mr Mathew Watkins, who is currently joint Company Secretary with Ms Leydin, will continue as the Company Secretary of the Company. Mr Watkins will provide the company secretarial services through specialist Company Secretarial, Governance and Accounting firm, Leydin Freyer Corp Pty Ltd of which Ms Leydin is the principal.

– ENDS –

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcm Markets.com and www.asx.com.au.

For Further information:

Mathew Watkins
Company Secretary
T: +61 3 9692 7222

Level 4, 100 Albert Road, South Melbourne, Vic 3205
Email: info@medibio.com.au | www.medibio.com.au